NASDAQ:GANX

Gain Therapeutics (GANX) Stock Forecast, Price & News

$4.93

+0.12 (+2.49%)

(As of 06/2/2023 ET)

Compare

Today's Range: $4.69
▼
$5.00
50-Day Range: $4.50
▼
$5.50
52-Week Range: $2.80
▼
$6.19

Volume: 47,730 shs
Average Volume: 57,177 shs
Market Capitalization: $60.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.15

Gain Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 65.3% Upside
$8.15 Price Target
Short Interest: Healthy
0.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.54) to ($1.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

304th out of 983 stocks

Pharmaceutical Preparations Industry

134th out of 486 stocks

3.4

Analyst's Opinion

Consensus Rating
Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.15, Gain Therapeutics has a forecasted upside of 65.3% from its current price of $4.93.
Amount of Analyst Coverage
Gain Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.57% of the float of Gain Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Gain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Gain Therapeutics has recently decreased by 7.86%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Gain Therapeutics does not currently pay a dividend.
Dividend Growth
Gain Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GANX.

2.8

News and Social Media Coverage

News Sentiment
Gain Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Gain Therapeutics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for GANX on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.00% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.21% of the stock of Gain Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.54) to ($1.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gain Therapeutics is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gain Therapeutics is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gain Therapeutics has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gain Therapeutics (NASDAQ:GANX) Stock

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GANX Stock News Headlines

June 1, 2023 | finance.yahoo.com

Gain Therapeutics to Present at the Jefferies Healthcare Conference

May 20, 2023 | americanbankingnews.com

Chardan Capital Brokers Cut Earnings Estimates for Gain Therapeutics, Inc. (NASDAQ:GANX)

June 3, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 17, 2023 | americanbankingnews.com

Research Analysts Set Expectations for Gain Therapeutics, Inc.'s Q4 2023 Earnings (NASDAQ:GANX)

May 16, 2023 | americanbankingnews.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Down 7.1% in April

May 15, 2023 | msn.com

Chardan Capital Maintains Gain Therapeutics (GANX) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

Where Gain Therapeutics Stands With Analysts

May 15, 2023 | markets.businessinsider.com

Analyst Expectations for Gain Therapeutics's Future

June 3, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 13, 2023 | finance.yahoo.com

Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

May 12, 2023 | finanznachrichten.de

Gain Therapeutics, Inc.: Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 12, 2023 | finance.yahoo.com

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2023 | finance.yahoo.com

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 8, 2023 | finance.yahoo.com

Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for

May 3, 2023 | marketwatch.com

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

May 3, 2023 | finance.yahoo.com

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

May 1, 2023 | msn.com

HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation

May 1, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Gain Therapeutics (GANX)

April 22, 2023 | finance.yahoo.com

Gain Therapeutics, Inc. (GANX) stock forecast and price target

April 12, 2023 | finance.yahoo.com

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

April 1, 2023 | americanbankingnews.com

Chardan Capital Weighs in on Gain Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:GANX)

March 30, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Gain Therapeutics (GANX)

March 29, 2023 | finance.yahoo.com

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

March 28, 2023 | finanznachrichten.de

Gain Therapeutics, Inc.: Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

March 27, 2023 | americanbankingnews.com

Chardan Capital Raises Gain Therapeutics (NASDAQ:GANX) Price Target to $5.75

March 23, 2023 | finance.yahoo.com

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

March 22, 2023 | finance.yahoo.com

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

See More Headlines

GANX Price History

30 days | 90 days | 365 days | Advanced Chart

GANX Company Calendar

Last Earnings: 3/23/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GANX
CUSIP: N/A
CIK: 1819411
Web: www.gaintherapeutics.com
Phone: 301-500-1556
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.15
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +65.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,590,000.00
Net Margins: N/A
Pretax Margin: -12,898.67%
Return on Equity: -92.98%
Return on Assets: -73.67%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 3.75
Quick Ratio: 3.75

Sales & Book Value

Annual Sales: $140,000.00
Price / Sales: 434.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.23 per share
Price / Book: 4.01

Miscellaneous

Outstanding Shares: 12,330,000
Free Float: 10,973,000
Market Cap: $60.79 million
Optionable: Not Optionable
Beta: 0.37

Key Executives

Dr. Khalid Islam Ph.D. (Age 67)
Founder & Chairman
Comp: $60k

Mr. Matthias Alder LIC. IUR. (Age 57)
LL.M., COO, CEO & Director
Comp: $414.29k

Mr. Salvatore Calabrese (Age 52)
CFO & Corp. Sec.
Comp: $345.39k

Mr. Gianluca Fuggetta (Age 34)
Principal Accounting Officer

Dr. Xavier Barril Ph.D.
Chief Technology Officer

Dr. Manolo Bellotto Ph.D. (Age 51)
GM & Chief Strategy Officer

Dr. Ana Maria Garcia-Collazo Ph.D.
Head of Research

Dr. Natalia Perez-Carmona Ph.D.
Head of Biology

Dr. Joanne Taylor Ph.D.
Sr. VP of Research & Scientific Advisor

Dr. Terenzio Ignoni Pharm.D.
Sr. VP of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GANX Stock - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares.
View GANX analyst ratings or view top-rated stocks.
What is Gain Therapeutics' stock price forecast for 2023?: 5 brokerages have issued 1-year price targets for Gain Therapeutics' shares. Their GANX share price forecasts range from $5.00 to $10.00. On average, they predict the company's share price to reach $8.15 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price.
View analysts price targets for GANX or view top-rated stocks among Wall Street analysts.
How have GANX shares performed in 2023?: Gain Therapeutics' stock was trading at $3.13 at the beginning of 2023. Since then, GANX stock has increased by 57.5% and is now trading at $4.93.
View the best growth stocks for 2023 here.
Are investors shorting Gain Therapeutics?: Gain Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 55,100 shares, a decline of 7.9% from the April 30th total of 59,800 shares. Based on an average trading volume of 83,600 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.6% of the shares of the stock are sold short.
View Gain Therapeutics' Short Interest.
When is Gain Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our GANX earnings forecast.
How were Gain Therapeutics' earnings last quarter?: Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02.

When did Gain Therapeutics IPO?: (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.
What is Gain Therapeutics' stock symbol?: Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX."
Who are Gain Therapeutics' major shareholders?: Gain Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.77%), CM Management LLC (0.74%), Renaissance Technologies LLC (0.32%), Raymond James & Associates (0.17%), Dimensional Fund Advisors LP (0.15%) and Susquehanna International Group LLP (0.12%).
View institutional ownership trends.
How do I buy shares of Gain Therapeutics?: Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gain Therapeutics' stock price today?: One share of GANX stock can currently be purchased for approximately $4.93.
How much money does Gain Therapeutics make?: Gain Therapeutics (NASDAQ:GANX) has a market capitalization of $60.79 million and generates $140,000.00 in revenue each year. The company earns $-17,590,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.
How can I contact Gain Therapeutics?: Gain Therapeutics' mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The official website for the company is www.gaintherapeutics.com. The company can be reached via phone at 301-500-1556 or via email at ir@gaintherapeutics.com.

This page (NASDAQ:GANX) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial